Viatris' Strategic Move: Acquiring Pacira BioSciences to Expand Non-Opioid Pain Management Solutions

Viatris Completes Acquisition of Pacira BioSciences


PITTSBURGH, Nov. 17, 2026
In a significant step towards enhancing its capabilities in innovative medicines, Viatris Inc. (Nasdaq: VTRS) has successfully finalized its acquisition of Pacira BioSciences, Inc. (Nasdaq: PCRX), a prominent player in non-opioid pain management solutions. This transaction, initially announced on October 8, 2026, reflects Viatris’s strategic direction to build a robust portfolio in areas of considerable unmet medical needs.

A Stronger Presence in Pain Management


Scott A. Smith, CEO of Viatris, expressed that this acquisition signifies a milestone for the company's strategy in the U.S. healthcare landscape. He stated, “With Pacira now part of Viatris, we are bringing together complementary portfolios, capabilities, and expertise to establish a leadership position in non-opioid pain management.”
This collaboration aims to create unique opportunities to enhance patient outcomes while accelerating Viatris's revenue growth trajectory. Pacira's innovative solutions are expected to integrate seamlessly into Viatris's existing offerings, ultimately benefiting a wider patient demographic seeking effective pain relief alternatives.

Details of the Acquisition


The tender offer for Pacira’s outstanding common stock expired as of November 16, 2026. Viatris had offered $36.50 per share in cash, and the response was overwhelming, with approximately 32 million shares tendered, accounting for roughly 66% of Pacira's total outstanding shares.
Following the completion of the tender offer, a merger occurred, solidifying Pacira as a wholly owned subsidiary of Viatris without requiring a vote from Pacira's stockholders. As a result, the remaining shares will be exchanged for the same offer price, concluding the transaction. Consequently, Pacira's shares will be removed from the Nasdaq Global Select Market.

Financial Implications and Future Outlook


Viatris anticipates the acquisition could generate significant revenue contributions, estimating between $90 million and $100 million for the remainder of 2026. This projection underlines the expected positive impact on Viatris's financial performance in the immediate term as they leverage Pacira’s expertise.

In his concluding remarks, Smith conveyed his enthusiasm about welcoming the talented professionals from Pacira, emphasizing the broader vision to enhance the company’s impact on patient care. “We are excited to welcome our new Pacira colleagues as we create new opportunities to make a meaningful difference for patients,” he added.

About Viatris


Viatris is dedicated to empowering patients globally to lead healthier lives by progressing in drug development and ensuring a resilient supply of necessary medications. Its diverse portfolio spans generics, branded medicines, and innovative products designed to address significant unmet health needs. Headquartered in Pittsburgh, with operational branches in global centers, Viatris aims to drive effective healthcare solutions at scale.

This acquisition of Pacira marks a turning point in Viatris's quest to enhance its offerings in the pharmaceutical landscape while addressing critical challenges in pain management. The growth trajectory ahead is poised to enhance both the company’s market position and its dedication to patient health across the globe.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.